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Abstract 
Introduction: Age-associated cognitive decline—or normal (non-pathological, 
normative, usual) cognitive ageing—is an important human experience which differs in 
extent between individuals. The determinants of the differences in age-related cognitive 
decline are not fully understood. Progress in the field is taking place across many areas of 
biomedical and psychosocial sciences. 
Areas of agreement and controversy: The phenotype of normal cognitive ageing is well 
described. Some mental capabilities are well maintained into old age. From early 
adulthood there are declines in mental domains such as processing speed, reasoning, 
memory and executive functions, some of which is underpinned by a decline in a general 
cognitive factor. There are contributions to understanding individual differences in 
normal cognitive ageing from genetics, general health and medical disorders such as 
atherosclerotic disease, biological processes such as inflammation, neurobiological 
changes, diet, and lifestyle. Many of these effect sizes are small; some are poorly 
replicated; and in some cases there is the possibility of reverse causation, with prior 
cognitive ability causing the supposed ‘cause’ of cognitive ability in old age. 
Emerging areas for developing research: Genome wide scans are a likely source to 
establish genetic contributions. The role of vascular factors in cognitive ageing is 
increasingly studied and understood. The same applies to diet, biomarkers such as 
inflammation, and lifestyle factors such as exercise. There are marked advances in brain 
imaging, affording better in vivo studies of brain correlates of cognitive changes. There is 
growing appreciation that factors affecting general bodily ageing also influence cognitive 
functions in old age. 
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Introduction 
The impact of age itself on cognition—not dementia, and not mild cognitive impairment, 
nor the other specific cognitive decline syndromes—is such a large, immediate problem 
for current science, and so ignored by current scientists, that Brayne (1) called it, “the 
elephant in the room.” 
 
With an increasingly aged population, both in the United Kingdom (UK) and 
internationally, cognitive impairment is a major health and social issue. Cognitive decline 
is among the most feared aspects of growing old. It is also the most costly, in terms of the 
financial, personal and societal burdens. It is important, because cognitive decline heralds 
dementia, illness and death. In the UK, cognitive failure is the cause for 40% of 
admissions to institutional care. It is widely agreed that more research is needed to 
understand the mechanisms of cognitive ageing and the factors that contribute to its 
individual differences (1). Committees have been formed and book-length calls have 
gone out from national organizations, enumerating the problems of the ageing brain, and 
the necessary research agenda: from the Scottish National Health Service (2), from the 
UK’s House of Lords (3), from the USA’s National Academies (4), and the USA’s 
National Institutes of Health (5). The latter stated that, “identifying the demographic, 
biological, and psychosocial factors that can help people maintain or enhance their 
cognitive and emotional health as they grow older becomes a major public health goal for 
this country” (p. 13). The present summary of some aspects of non-pathological cognitive 
ageing focusses on studies that have examined older people. However, the state of the 
brain in old age is the summary of effects across the lifecourse, from conception. This 
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long view is well represented in the UK Government Office for Science’s Foresight 
Report, ‘Mental Capital and Wellbeing’ (6), and it is highly recommended. 
 
The above-mentioned sources (1-6) on cognitive ageing and its causes make it clear—to 
a greater or lesser extent—that it is far from straightforward to separate non-pathological 
from pathological cognitive decline. Often, in the studies that are summarized below, this 
is done by brief tests such as the Mini-Mental State Examination, and/or by the absence 
of a clinical diagnosis, and sometimes by exclusion using a standardised psychiatric 
interview. However, it is recognized and must be remembered that: people’s differences 
in age-related cognitive decline form a continuum, not entirely discrete groups (of course, 
defining into groups is needed for treatment decisions); diagnostic criteria for Mild 
Cognitive Impairment (and its alternative terms) and dementia change, and so the points 
on the continuum that are deemed pathological or not can change; people’s cognitive 
level in old age depends to a large extent on their prior intelligence and that is not always 
taken into account in reckoning whether a given level of cognitive function in old age 
represents a decline—in absolute terms, or relative to their age cohort—for that person; 
the same measured level of cognitive ability in old age can occur in the presence of very 
different levels of brain pathology (e.g. Alzheimer-type); and even people with no 
apparent cognitive decline can have Alzheimer-type pathology in their brains. In 
summary, studies that purport to describe contributions to non-pathological cognitive 
ageing must be examined with these caveats, and bearing in mind the possibility that 
some people in such studies might be in the early, undiagnosed stages of pathological 
cognitive impairment. 
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If the first warning about studies in non-pathological cognitive ageing is that the subjects 
in such studies will not invariably be non-pathological, the second warning is that 
apparent causes of cognitive ageing will not always be causes at all. It is quite common to 
read a report in which a variable is associated significantly with a cognitive test score in 
old age. Typically, the study is cross-sectional. Typically, too, the suggestion is made that 
the variable is a possible cause of cognitive differences in old age, of cognitive decline 
perhaps. It might be. But there are other possibilities. The follow-up studies of the 
Scottish Mental Surveys (7), for example, have shown that intelligence test scores from 
childhood are associated with health variables and health risk factors in middle and old 
age. Therefore, the cross-sectional ‘variable X versus cognitive ability scores’ finding in 
old age might—in part or whole—be the result of reverse causation: intelligence traits 
from early life affect later health. Another possibility is that the cross-sectional 
correlation is caused by some third—confounding—variable or set of variables, and that 
the correlation is spurious, being the result of some more basic factor(s) that affect both 
the apparent cause and effect. Therefore, discovering associations between putative 
causes of cognitive ageing and cognitive ability test scores are only the beginning. 
Ideally, they should be studied longitudinally and be the subject of mechanistic 
investigations. 
 
The landscape of cognition and how it ages 
There is little age-associated decline in some mental functions—such as verbal ability, 
some numerical abilities, and general knowledge—but other mental capabilities decline 
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from middle age onwards, or even earlier (8,9). The latter include aspects of memory, 
executive functions, processing speed, and reasoning. All of these so-called ‘fluid’ mental 
abilities are important for carrying out everyday activities, living independently, and 
leading a fulfilling life. When one fluid mental domain declines others tend to do so also 
(10). Second, slowed speed of information processing appears to account for a substantial 
proportion of age-associated decline in all affected cognitive domains, and the slowing 
has begun by the 30s (11), as has the age-associated decline in some other aspects of 
cognitive function (12). Within the range defined by ‘normal cognitive ageing’—i.e. in 
people who would not meet the criteria for dementia or any of the varieties of ‘mild 
cognitive impairment’—people differ greatly in the degree to which their brains decline 
with age. Identifying the risk factors for, and mechanisms of, individual differences in 
age-associated cognitive decline is amongst the greatest challenges to improving the 
wellbeing of older people. 
 
Here we address some contributions—general medical, genetic, vascular, physiological, 
dietary, and lifestyle—to non-pathological cognitive ageing. This is an especially 
important problem because it involves such large numbers of people compared with the 
dementias. The USA’s NIH emphasised the importance of studying the processes of 
“normal” and “successful” cognitive ageing (5). We should state at the start that 
individual differences in cognitive ability in old age reflect two things: differences in 
prior cognitive ability and differences in the degree to which change (typically 
deterioration) has taken place. Of the many possible contributors to cognitive ability level 
in old age, none yet known approaches the effect size of mental ability measured in 
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childhood. Even as late as age about 80, childhood intelligence contributes about 50% of 
the variance, or more, to cognitive ability in old age in people without dementia (7). 
 
Disease, health and normal cognitive ageing 
Inasmuch as age is the major risk factor for dementing illnesses, such as Alzheimer’s 
disease, there is a case for considering these as representing an extreme end of the 
spectrum of age-associated cognitive decline. However, the dementias are not only 
quantitatively different in the degree of cognitive decline, they are often qualitatively 
different in the pattern of decline across the various cognitive abilities. For example, 
Alzheimer’s disease is characterized by marked impairment of episodic memory, and 
frontotemporal dementia by impaired executive function. Moreover, people with 
dementia often exhibit changes in behaviour and other aspects of mental state as well as 
declines in performing activities of daily living. Having said this, in advanced old age, 
when dementia has a high prevalence, distinguishing between normative and non-
normative ageing is not simple. Indeed, this difficulty has been recognized by introducing 
categories such as mild/minimal cognitive impairment which have a position somewhere 
between normal cognitive ageing and dementia. 
 
One problem in distinguishing between normative and non-normative cognitive ageing is 
that neuropathological changes of Alzheimer’s disease are widespread in older peoples’ 
brains. In the MRC Cognitive Function in Aging Study (CFAS), around one third of 
participants without dementia had moderate or severe neuritic plaque scores at autopsy 
(13). Another challenge is the observation that risk factors for dementia also increase risk 
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of normative cognitive decline (age, hypertension, diabetes, physical fitness, and 
education) (1,5,6,7). Mirroring the problems distinguishing normative and non-normative 
cognitive ageing is a similar set of challenges differentiating normal physical ageing from 
age-associated disease. Disease, as defined by diagnosis and excepting dementia, is a 
poor predictor of cognitive decline (14), whereas physiological markers of health status 
are significantly correlated among themselves and with cognitive ageing (15). This 
mirroring has suggested that physiological and cognitive functions decline together in old 
age, and led to what is termed the ‘common cause’ theory of ageing. This theory 
hypothesizes that, whereas there are individual measure-specific mechanisms leading to 
decline, a considerable proportion of decline is attributable to some core biological 
processes that deteriorate with ageing. Candidates for such core processes include 
oxidative stress, telomere attrition, hormonal dysregulation and immunosenescence. 
Research on the relationship between physical and cognitive ageing has thus sought to 
measure biomarkers of these processes to establish which pathways are implicated. 
 
Another problem has been recognized that impacts upon our understanding of the 
relationship between physical health and age-associated cognitive decline: several disease 
states thought to affect cognition adversely are more common in people with lower early 
life IQ, including childhood IQ (7). Since childhood IQ, itself, is a strong predictor of 
cognitive abilities in later life, the disease state may be acting as a marker of lower 
childhood IQ and this might explain in whole or in part any association with lower 
cognitive ability in old age. For example, lower childhood IQ is associated with elevated 
blood pressure in middle age even after adjustment for social class, smoking and other 
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factors (16). High blood pressure is thought to lead to cognitive decline, but few studies 
that examine this relationship adjust for the contribution made by childhood IQ to 
cognition in later adult life. Hence age-associated cognitive decline is best considered in 
terms of a lifecourse perspective. What appears to be the effect of an illness state on 
cognitive ability in old age might in part be the reverse: the effect of early life cognition 
on the risk of developing the disease state. 
 
Genetic contributions to cognitive ageing 
Heritability studies—using data from twins and families with adopted children—have 
estimated that the heritability of general cognitive ability is ~50%, increasing from 
childhood to adulthood and into old age. Some studies have shown that heritability 
decreases in very old age, though the contribution of genes to cognitive ability remains 
above 50%. It is likely that there are genetic influences on both the life-long trait of 
intelligence and specifically on age-associated cognitive decline (17,18).  
 
Candidate genes studies have looked for associations between variations in specific genes 
and age-associated cognitive decline. Candidate genes include those previously 
associated with cognitive ability, dementia, cardiovascular disease, oxidative stress and 
longevity (17).  There have been a number of published associations between candidate 
genes and cognitive ageing, but the gene coding for apolipoprotein E (APOE), a risk 
factor for Alzheimer’s disease, is one of the few to have been replicated in multiple 
studies (19,20). In people within the normal range of cognitive ageing, possession of the 
E4 allele of the APOE gene perform slightly worse on general cognitive ability, and on 
 10 
the specific domains of perceptual speed, episodic memory, and executive functioning. 
The influence of specific variants in ten genes—for example BDNF, COMT, DISC1 and 
PRNP—that had been previously associated with cognitive ageing, cognitive ability, 
Alzheimer’s disease and autism, were recently examined, and there was no evidence that 
they were associated with cognitive ageing in a cohort of ~1000 Scots with cognitive 
ability test scores available from ages 11 and 70 years (21). There are several reasons 
why candidate gene studies have identified so few replicable associations with age-
associated cognitive decline. First, the genetic variants so far identified each account for 
at most only a small percentage (1-2%) of the variance in cognitive ageing and, as most 
studies contain only hundreds of participants, they are often underpowered for detecting 
such effect sizes. Second, many of the studies have been performed on participants from 
different populations and it is possible that different genes are important in different 
populations. Third, not all studies have used participants of the same age range. It may be 
that different genes influence cognition at different ages, even within what is classified as 
old age. Finally, the major limitation of candidate genes studies is that they rely on our 
limited understanding of both the biology of cognitive ageing and the functions of the 
candidate genes. This is where genome-wide association studies will be more useful, 
allowing up to one million genetic variants (both single nucleotide polymorphisms and 
copy number variations) spread throughout the genome to be genotyped. They are not 
biased towards a particular gene or genes (22). Table 1 summarises and exemplifies 
genetic approaches to the study of non-pathological cognitive ageing. 
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Cardiovascular disease and cognitive ageing 
A delicate relationship exists between the circulatory system and the brain which, if upset 
by vascular disease, may affect normal brain functioning (23). Diverse neurological 
symptoms may follow either transient or permanent disruption of blood flow to the brain. 
Long-lasting sensorimotor and behavioural disabilities are frequently observed after acute 
ischaemic stroke caused by complications of large-artery atherosclerosis (24). A single 
large or repeated brain infarcts increase the risk of cognitive impairment, hence the term 
multi-infarct dementia. Even without dementia, stroke patients tend to perform poorly on 
cognitive tests compared to healthy, non-stroke controls. Depending on the criteria used, 
cognitive impairment may affect up to 70% of patients (25). Deficits in multiple 
cognitive domains are frequently observed, including general mental status, abstract 
reasoning, attention, and specific memory functions, but usually some improvement 
occurs with time following the stroke event. Different stroke characteristics, including 
lesion laterality, may also influence cognitive outcomes in these patients; for example, 
left-hemisphere stroke is consistently associated with general cognitive impairment (24). 
Although focal neurobehavioural deficits are common after stroke, general mental 
functions which depend on the integrity of the entire brain may also be affected. 
 
Symptomatic atherosclerotic disease in one arterial site may represent similar pathology 
in other arteries (23). For example, stroke patients frequently have concomitant coronary 
heart disease (CHD). Even in the absence of stroke, CHD predisposes to cognitive 
impairment which, in addition to systemic atherosclerosis, may result from cerebral 
hypoperfusion due to impaired cardiac function or infarcts caused by cardiogenic emboli 
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travelling to the brain (23). Although few studies have examined cognitive deficits in 
patients with milder CHD syndromes—including angina—poorer mental status, memory 
and executive function have been reported in survivors of acute myocardial infarction 
(AMI) (23). However, known CHD risk factors, which often cluster in individual 
patients, may independently influence cognition. When appropriately controlled for, AMI 
may no longer associate with cognitive performance (26). In contrast, end-stage 
congestive heart failure is associated with deficits in executive function, memory, 
concentration, and psychomotor speed (23). Cardiac output, which may be severely 
reduced due to impaired ventricular function, predicts cognitive function in these 
patients, although as yet, it is unknown whether heart transplantation actually improves 
cognitive outcomes in patients with long-standing heart failure. 
 
Similarly, patients with peripheral arterial disease (PAD) affecting the lower extremities 
commonly have atherosclerotic lesions in major arteries supplying the heart muscle and 
the brain. Deficits in psychomotor speed, problem solving and abstract reasoning are 
common in neurologically-intact patients with very advanced PAD, such as leg amputees 
(27). The extent of these deficits may differ only marginally from that seen following 
overt stroke. In these patients, disease severity may be an important predictor of cognitive 
function. In population-based studies, elderly people who experience leg pain while 
walking, the clinical hallmark of PAD, have been found to be at an increased risk of 
progressive cognitive decline, particularly in verbal memory, which is not explained by 
the influence of a previous stroke, depressed mood, or concomitant vascular risk factors 
on cognition (26). 
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Inflammation and cognitive ageing 
There is strong evidence linking markers of inflammation with atherosclerosis and 
cardiovascular disease, but its relationship with cognition is less well defined. Current 
prospective and cross-sectional studies provide conflicting views with positive and null 
findings being reported between late-life biomarker levels and cognitive ability (28,29). 
Of these studies, few have assessed a large cohort of subjects over a long-term follow-up 
using an extensive battery of cognitive tests.   
 
In terms of the inflammatory biomarkers studied, there is a reasonably large body of 
work on the downstream acute-phase protein C-reactive protein (CRP), and the upstream 
cytokines tumor necrosis factor alpha and interleukin-6.  The magnitude of the effect 
sizes between these markers and cognition is typically small, with the biomarkers 
explaining approximately 1% of the variance of the cognitive test scores. In addition to 
inflammatory biomarkers, some studies have also integrated rheological and thrombotic 
factors, such as plasma viscosity and fibrinogen into their analyses. Initial findings for 
these markers are again mixed although a causal rheology-cognition association is 
certainly plausible via a ‘sticky blood’ hypothesis. Explicitly, some suggest that increased 
blood viscosity has an effect on cerebral blood flow at a microvascular level (30).   
 
One study showed associations between both CRP and fibrinogen with cognitive ability 
at age 70 years (31). However, upon adjustment for a measure of IQ at age 11, the 
associations were markedly attenuated. Further, the age-11 IQ scores also predicted age-
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70 CRP levels. This again raises the possibility of a reverse causation argument, in which 
lower childhood IQ leads to more inflammation in later life. Longitudinal data such as 
these are clearly a desirable study feature, although investigators might also consider the 
inclusion of a vocabulary based test to estimate peak prior cognitive function. Measures 
such as the National Adult Reading Test are fairly robust estimates with scores on 
vocabulary based tests showing little evidence of change over time (32). 
 
Given the high variability and acute nature of some inflammatory biomarker levels in old 
age, especially CRP, it may be relevant to use genetic variants as predictors of lifetime 
exposure to inflammation. Such an approach treats the intermediate phenotype (the 
biomarker level, such as CRP) as a biased measure. Instead, it models directly a gene-
cognition association using genetic information, such as single nucleotide 
polymorphisms. Because genetic variants are determined at conception, they are less 
likely to be affected by confounding. Therefore, the use of such variants as predictors 
may be an approach that will help to elucidate causal mechanisms. A caveat with this 
approach is the very large sample size required to detect significant associations. It may 
be that collaborative work with replication across different populations is required to 
reduce the possibility of false positive findings and to ensure adequate power to detect 
what are almost certain to be small associations. 
 
Neurobiology and cognitive ageing 
The brain undergoes pronounced age-associated structural changes in old age. The most 
obvious is a steady decrease in brain size, balanced by an increase in ventricular spaces 
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and cerebrospinal fluid. Brain atrophy accelerates in old age and shows an anterior-
posterior gradient, with the most severe effects occurring in prefrontal regions (33). 
Compared with overall brain, age-associated shrinkage is much smaller in the cerebral 
parenchyma. In the latter, atrophy starts much earlier in life and is more steady in grey 
matter (the neuron cell bodies) and cortical thickness than in white matter (the nerve 
fibres connecting different brain areas). Brain white matter volume tends to be relatively 
stable in healthy adults until about age 70, when steep decline, with an even more 
pronounced anterior-posterior gradient, can set in (8,33,34). Also, cerebral dopamine 
receptor density depletes with age, which plays a central role in regulating attention and 
in modulating response to contextual stimuli (8). A variety of mechanisms are likely to be 
causal in the normative age-associated decline of brain structure, including hypertension, 
age-associated vascular and microvascular changes, oxidative stress, recurrent 
inflammation, and stress-related corticosteroid levels (33,35). 
 
It has been proposed that the loss of white matter integrity is an especially critical factor 
in normal cognitive ageing, since it leads to impaired information transfer between 
different cortical areas, from a loss of transfer speed in the case of demyelination to 
complete disconnection when axonal disruptions occur. Interactions between distant 
cortical areas are considered as crucial for the emergence of higher cognitive functions 
(34). Until recently, problems with white matter integrity could mainly be detected as 
lesions that appear as hyperintensive patches on structural magnetic resonance imaging 
(MRI) scans and were mostly quantified using visual rating scales. Even though this 
procedure is laden with various measurement issues, small but consistent relationships 
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with higher cognitive functions have been detected this way (36). The advent of various 
new neuroimaging techniques, most notably diffusion tensor MRI, now allow for a much 
more detailed look at microstructural changes in cerebral white matter, including fibre 
tract-specific assessments of white matter integrity (quantitative tractography) (34). 
However, despite these technological advances, the studies to date report associations 
between structural brain differences and cognitive ability measures in old age that tend to 
be modest in size and sometimes elusive (8,33,34). 
 
Two major explanations have been brought forward for this rather surprising pattern of 
results. First of all, people are assumed to differ in their cognitive reserves, which can be 
defined as the brain’s capacity to buffer the effects of insults. The main determinants of 
cognitive reserve are early-life cognitive ability (the ‘baseline’), education level, and 
occupational complexity, with the former being a strong predictor of the latter two 
(12,35). Secondly, it is assumed that the ageing brain compensates structural losses in 
functional areas by recruiting previously unrelated parts of the brain (preferably in the 
prefrontal cortex and in corresponding contra-hemispheric areas) to take over the role in 
cognitive functions (8,34). Both accounts have received some empirical support 
(8,34,35), so they might explain why normative age-associated structural brain changes 
do not inevitably lead to cognitive decline. 
 
Diet, lifestyle, and cognitive ageing 
The role of diet and other lifestyle factors in successful brain ageing has been attracting 
increasing scientific and public interest. Recent findings suggest that improving the diet 
 17 
of older people might help to delay the onset, or slow the progression, of age-associated 
cognitive decline. Current research has focussed on the role of specific dietary elements, 
and dietary patterns.  
  
Some research supports the importance of a diet rich in B-vitamins, antioxidants and 
omega-3s for mental fitness. B-vitamins are essential for maintaining normal brain 
function and memory. Epidemiologic data suggest a protective role for B vitamins, 
particularly vitamin B12, B6 and folate (B9) on cognitive function. Moreover, B-vitamins 
help to regulate homocysteine levels, which is a risk factor for cognitive decline (37). 
Oxidative damage has been implicated in ageing and age-associated cognitive decline. 
Dietary antioxidants (such as vitamins C, E, beta-carotene and flavonoids) found in fruits 
and vegetables may help protect against oxidative damage by boosting antioxidant 
defences. Evidence from cross-sectional studies supports a link between antioxidant 
status and cognitive function in older people (38). In addition to antioxidant vitamins, 
fruits (such as blueberries) and vegetables contain plant polyphenols—compounds 
thought to interact with ageing neurons, increasing their capacity to maintain proper 
functioning during ageing (39). Omega-3 fatty acids (particularly DHA) are highly 
concentrated in the brain and the habitual consumption in later life of oily fish, rich in 
omega-3s, is associated with a reduced risk for cognitive decline and dementia (37, 40). 
They have been found to have anti-inflammatory, antioxidant and neuro-protective 
properties. Experimental evidence supporting a cognitive benefit to micronutrient 
supplementation in old age has been inconclusive. However, nutritional intake is based 
on a complex interaction of both macro- (proteins, fats, carbohydrates) and 
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micronutrients (vitamins, minerals). For that reason, some researchers have directed their 
attention to the effects of dietary patterns. Prevailing scientific opinion points to a pattern 
of intake reflected in a ‘Mediterranean diet’—rich in vegetables, legumes, fruit, nuts, 
cereals, fish and moderate amounts of alcohol (particularly red wine) and low in meat, 
poultry and dairy products—to maximize one’s cognitive abilities into old age. 
Conversely, a diet high in refined sugars, cholesterol and trans-fats might be associated 
with poorer cognitive outcomes in older adults (37). The interaction between genes and 
nutrition in recent research highlights the interplay between internal and external 
environments. Cognitive benefits were found in older adults consuming omega-3 fatty 
acids but only in non-APOE e4 carriers (41). This finding supports the concept of an 
individual response to dietary intake and heterogeneity in cognitive ageing. 
 
In conjunction with diet, other lifestyle factors such as smoking, drinking, physical 
activity and sleep, influence cognitive ageing (6,12). Evidence is growing that moderate 
levels of alcohol intake in older people can be beneficial; they are associated with better 
cognitive performance than either abstinence or heavy drinking and may have a 
protective effect against dementia and cognitive decline (42). This risk reduction is partly 
attributable to the protective effects of alcohol on cardiovascular and cerebrovascular 
health. Smoking, primarily via detrimental effects on vascular disease, is a significant 
risk factor for cognitive impairment.  A dose-response effect is evident for the number of 
cigarettes smoked during the lifetime and the degree of cognitive decline (43). Giving up 
smoking at any age may prevent further smoking induced cognitive harm. 
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Future research should consider the full impact of socio-demographic factors; education, 
for example, is known to shape food choices in adulthood and therefore plays an 
important confounding role in the relationship between diet and cognition. While further 
investigation is needed to clarify whether specific nutrients help to protect the brain from 
damage and counteract the effects of ageing, human epidemiologic studies provide some 
supporting evidence that a diet rich in plant matter and fish could offer protection against 
cognitive decline. 
 
Active lifestyle and cognitive ageing 
When considering potential determinants of age-associated cognitive decline, engaged 
and active lifestyles are often reported as protective (44). This may be of particular 
interest to clinicians, and indeed the public more generally, as it presents opportunities 
for delivered interventions or purposeful changes to habits intended to reduce cognitive 
decline. A recent UK Government review incorporated research linking physical activity 
or exercise and cognitive function, the consensus being that age-associated cognitive 
decline is apparently delayed or reduced in more physically active individuals (6). An 
important caveat to this is that the physical activity need not be strenuous; individuals 
who walk more may experience less decline in later life (6,44). Further investigation is 
warranted, particularly to examine whether there are critical periods across the lifespan 
when physical activity needs to be initiated and maintained, and what type of physical 
activity (e.g., aerobic versus anaerobic) might confer the greatest benefits (6). Not all 
studies report an exercise-cognitive decline association, perhaps due to variability in the 
physical activity measurements, the validity of the cognitive assessments and length of 
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follow-up in old age, and the timing and duration of the physical activity itself (44). That 
said, there are a number of mechanistic hypotheses which could account for an 
association between increased physical activity and reduced cognitive decline. Most 
notably, cardiovascular risk and disease profiles are known to play a role in the trajectory 
of cognitive decline in later life; physical activity lowers these risk factors (6,44,45). 
 
Participation in activities of a mental or intellectually stimulating nature has also been 
shown to predict reduced cognitive decline. In this domain, the notion of ‘use it or lose it’ 
is proposed: the continued deployment of cognitive abilities through activities requiring 
cognitive effort may have direct effects on the brain, in terms of structure and/or function 
(44,46). This is closely linked to the ‘cognitive reserve’ hypothesis. Individuals who are 
more cognitively active or engaged may accrue greater ‘reserve capacity’ across the 
lifecourse, and subsequently delay the onset of age-associated cognitive decline or reduce 
the impact of this (6,35). However, any association found between mentally stimulating 
activities and cognitive decline must be clearly shown to be independent of premorbid 
cognitive function (47). That is, the association must not be driven by the fact the higher 
ability individuals are more likely to be cognitively active throughout life and into old 
age (not just in terms of leisure but occupationally also); another example of possible 
reverse causation. The presumed protective effect may be due to the high degree of 
stability in cognitive function across the lifespan, and not from participation in the 
activities themselves. To examine if there is truly a protective effect, more studies are 
needed which are able to control for an early measure of premorbid cognitive function. 
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The reason such activities are of particular interest derives from the fact that they may 
suggest simple, cost-effective lifestyle interventions to ameliorate or delay age-associated 
cognitive decline. To date, however, cognitive intervention trials have not produced 
robust, replicable benefits. A recent review including 10 randomised control trials 
reported a mean effect size of 0.16 across a range of interventions, although the authors 
noted that most studies failed to include matched, active controls or placebos, and that the 
benefit of the intervention often failed to generalise across varied cognitive outcomes 
(48). Few studies included a lengthy follow-up to determine whether any apparent short-
term gains in cognitive test performance were reflected at a more distal time point. This 
area will benefit from increased scrutiny and well-designed trials. Furthermore, it should 
be remembered that any beneficial interventions suggested need the compliance of those 
at risk in real world settings, as with other forms of medical treatment or medication use. 
Such behaviours are confounded by the ability to seek out and comprehend the 
information provided. 
 
Conclusion 
The interest in cognitive ageing is as understandable as it is compelling, for personal, 
scientific and practical interest. Personally, as we become aware of cognitive processes 
deteriorating, we witness the diminishing of something at the core of our rational self. 
Scientifically, it is a fascinating problem, namely to construct the multivariate recipe for 
successful cognitive ageing. Practically, demographic changes mean that our care 
services and economies will be better placed to cope with the increasing burden of 
cognitive ageing if there are clues to amelioration and prevention. Some contributions to 
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cognitive ageing are clearly more open to intervention than others: smoking, exercise, 
and diet can be changed following advice. Mechanistically, even the contributions from 
genetics and from childhood intelligence should not be looked on too pessimistically; 
even these factors have mechanisms which might afford interventions. 
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Table 1 
Types of genetic contributions to understanding non-pathological cognitive ageing. 
 
Types of 
Genetic 
Studies 
Targets Example results Future References 
Heritability 
studies 
Genetic influences on cognitive ability 
studied using twin, adoption and family 
designs. 
Genetic contributions to 
intelligence variation are: 
41% childhood; 
55% adolescence; 
66% in young adulthood; 
About 60% in old age 
 
* Determine source of 
heritability by searching 
for molecular genetic 
influences  
 
14,49 
Candidate 
gene studies 
Genes for cognitive ageing sought among 
genetic influences on: cognitive ability; 
dementia and other neurodegenerative 
disorders; cardiovascular disease; oxidative 
stress; longevity; etc. 
 
Variants in the following 
genes reported as associated 
with differences in cognitive 
ageing: APOE, BDNF, 
COMT, DISC1, PRNP 
* APOE is well 
established 
* Other genes have 
largely failed to 
replicate  
15-17 
Whole 
genome 
association 
Whole genome analysis used to reveal 
common variants influencing cognitive 
ageing 
LRP1B haplotypes associated 
with successful ageing 
without cognitive decline 
* Replication in larger 
samples 
* Improved genome 
coverage  
* Detailed cognitive 
testing  
50 
  
Note. The gene names are as follows: APOE is apolipoprotein E; BDNF is brain derived neurotrophic factor; COMT is catechol-O-
methyltransferase; DISC1 is disrupted in schizophrenia 1; PRNP is prion protein; and LRP1B is low density lipoprotein-related protein 
1B. 
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Table 2 
Some other potential contributors to non-pathological cognitive ageing. 
 
Potential contributor Details 
Self-reported health 
status 
Individuals reporting poorer health status experience greater cognitive decline. Likely mechanisms would 
implicate increased burden of cardiovascular disease and its risk factors, increased levels of inflammatory 
and oxidative stress markers, etc. (see below).  
Cardiovascular 
disease and its risk 
factors 
Normal cognitive functioning affected by vascular disease, for example, by disruption of blood supply to the 
brain after stroke, or atherosclerotic lesions in major arteries. Risk factors including high blood pressure also 
associated with poorer cognitive function, although caution needed as earlier cognitive ability itself may be 
predictive of the presence/severity of risk factors in later life, an example of possible reverse causation. 
Physiological markers 
of health status 
Associations between physiological markers of health (including inflammation, oxidative stress, etc.) and 
cognitive decline, are often discussed in terms of the common cause hypothesis: this suggests there may be 
shared biological processes of decline across domains of physical and cognitive health. It is necessary to 
identify biomarkers of decline processes to elucidate potential pathways. Markers of inflammation (i.e. CRP, 
IL-6, TNF-α) are linked to cardiovascular disease and atherosclerosis, but associations with cognitive 
decline are in need of further study. There are indications that levels of some markers in old age may be 
predicted by earlier cognitive function; possible reverse causation. 
Diet and nutrition Some research links diets higher in B-vitamins, antioxidants and omega-3s with higher cognitive function. 
Mechanisms for association could include regulation of homocysteine or oxidative stress pathways; 
however, experimental studies are inconclusive. ‘Mediterranean diet’ is thought to be protective—with the 
presence of vegetables, fish and moderate alcohol. 
Smoking and alcohol Smoking increases the risk of vascular disease, and thus has been linked to poorer cognitive health; 
moderate alcohol consumption appears to be, if anything, beneficial. 
Activity participation 
and physical fitness 
Active and engaged lifestyles seen as beneficial for later cognitive function, with particular emphasis on 
physical activity, which may reduce likelihood of CVD or related conditions, and also association between 
measures of physical fitness and cognition, again thought to be part of ‘common cause’ hypothesis of 
ageing. Mental engagement is often promoted as one of the key ingredients for successful cognitive ageing; 
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however, there are large potential confounds in terms of participation in these activities and earlier level of 
cognitive ability. Suggested mechanisms often cite direct effects of mental stimulation on brain structure and 
function. 
Education and social 
class 
More years spent in formal education and higher social class are associated with less cognitive decline. 
Mechanisms could include increased ‘cognitive reserve’ through educational and occupational trajectories, 
safer working and living environments, access to better health care, etc. Both factors are highly corelated, 
and likely to be partly predicted by earlier cognitive level. 
 
